project id: TCGA-PRAD; case submitter id: TCGA-ZG-A9L5; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.88; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.66; rna integrity number: 8.9; age at index: 58; days to birth: -21293; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1953; age at diagnosis: 21293; ajcc clinical m: M0; ajcc clinical t: T2a; ajcc pathologic n: N1; ajcc pathologic t: T4; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 908.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 5; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2011; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 953; initial weight: 460.0; sample id: 1b59308e-48cc-4bd9-b990-c82154487522; sample submitter id: TCGA-ZG-A9L5-01A; portion id: 9abd9712-bd28-40ce-8b4e-f64ef8b278ce; portion submitter id: TCGA-ZG-A9L5-01A-12; slide id: 274fc8f8-bf56-41c1-892d-316d4e55ccf9; slide submitter id: TCGA-ZG-A9L5-01A-01-TSA; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 30.0; percent tumor cells: 70.0; percent tumor nuclei: 80.0; section location: TOP;